Lundbeck posts strong 1st-qtr results
Danish CNS specialist Lundbeck (LUND: CO) edged up 1.3% to 34.27 kroner this morning, after the company released financial results for the first quarter of 2023, showing that sales increased by 15% (+11% at constant exchange rates) to 5,044 million kroner ($855 million), with all regions growing and the USA and Europe contributing strongly.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) increased to 1,845 million kroner (+43%; +39% CER) and adjusted EBITDA margin reached 36.6% equivalent to an increase of 7.1 percentage points. Adjusted earnings per share (EPS) reached 1.36 kroner equivalent to an increase of 33%.
The growth of Lundbeck’s strategic brands grew further with an increase of 23% (+19% CER), reaching 3,273 million kroner, representing 65% of total revenue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze